Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Nanofabrications of Erythrocyte Membrane-Coated Telmisartan Delivery System Effective for Radiosensitivity of Tumor Cells in Mice Model

Open access
Chen, Shaoqing, Wang, Cheng, Meng, Yanyan, Li, Pengyin, Pan, Yiwen, He, Mu, Ni, Xinye · 2024 · International Journal of Nanomedicine

Abstract

Background: Radiation stimulates the secretion of tumor stroma and induces resistance, recurrence, and metastasis of stromal-vascular tumors during radiotherapy. The proliferation and activation of tumor-associated fibroblasts (TAFs) are important reasons for the production of tumor stroma. Telmisartan (Tel) can inhibit the proliferation and activation of TAFs (resting TAFs), which may promote radiosensitization. However, Tel has a poor water solubility. Methods: In this study, self-assembled telmisartan nanoparticles (Tel NPs) were prepared by aqueous solvent diffusion method to solve the insoluble problem of Tel and achieve high drug loading of Tel. Then, erythrocyte membrane (ECM) obtained by hypotonic lysis was coated on the surface of Tel NPs (ECM/Tel) for the achievement of in vivo long circulation and tumor targeting. Immunofluorescence staining, western blot and other biological techniques were used to investigate the effect of ECM/Tel on TAFs activation inhibition (resting effect) and mechanisms involved. The multicellular spheroids (MCSs) model and mouse breast cancer cells (4T1) were constructed to investigate the effect of ECM/Tel on reducing stroma secretion, alleviating hypoxia, and the corresponding promoting radiosensitization effect in vitro. A mouse orthotopic 4T1 breast cancer model was constructed to investigate the radiosensitizing effect of ECM/Tel on inhibiting breast cancer growth and lung metastasis of breast cancer. Results: ECM/Tel showed good physiological stability and tumor-targeting ability. ECM/Tel could rest TAFs and reduce stroma secretion, alleviate hypoxia, and enhance penetration in tumor microenvironment. In addition, ECM/Tel arrested the cell cycle of 4T1 cells to the radiosensitive G2/M phase. In mouse orthotopic 4T1 breast cancer model, ECM/Tel played a superior role in radiosensitization and significantly inhibited lung metastasis of breast cancer. Conclusion: ECM/Tel showed synergistical radiosensitization effect on both the tumor microenvironment and tumor cells, which is a promising radiosensitizer in the radiotherapy of stroma-vascular tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s441418

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Fabrication and characterization of ECM/Tel. (A) Fabrication steps of ECM/Tel. (B) Particle size variation of different formulations of ECM/Tel, with the mass ratio of Tel and membrane protein content of ECM was 0.5:1, 1:1, and 2:1, respectively. (C) Coomassie blue staining results of ECM/Tel. (D and F) TEM and particle size results of self-assembled Tel NPs (left), ECM (middle), and ECM/Tel (right). Red arrows indicate the membrane-mimic structure. Scale bar = 100 μm.
Figure 1 Fabrication and characterization of ECM/Tel. (A) Fabrication steps of ECM/Tel. (B) Particle size variation of different formulations of ECM/Tel, with the mass ratio of Tel and membrane protein content of ECM was 0.5:1, 1:1, and 2:1, respectively. (C) Coomassie blue staining results of ECM/Tel. (D and F) TEM and particle size results of self-assembled Tel NPs (left), ECM (middle), and ECM/Tel (right). Red arrows indicate the membrane-mimic structure. Scale bar = 100 μm.CC BY-NC · PubMed Central
Figure 2 Cytotoxicity, cellular uptake and in vivo distribution of ECM/Tel. (A) Cytotoxicity of ECM/Tel against NIH/3T3 and A-NIH/3T3 cells. (B) Time-dependent cellular uptake of ECM/Tel in A-NIH/3T3. Scale bar: 50 μm. (C) In vivo distribution of ECM/Tel in mouse orthotopic 4T1 breast cancer model. Red circle: tumor area. (D) Fluorescence distribution of organs and tumors after dissection. (E) Semi-quantitative analysis of tumor fluorescence. ***P < 0.001.
Figure 2 Cytotoxicity, cellular uptake and in vivo distribution of ECM/Tel. (A) Cytotoxicity of ECM/Tel against NIH/3T3 and A-NIH/3T3 cells. (B) Time-dependent cellular uptake of ECM/Tel in A-NIH/3T3. Scale bar: 50 μm. (C) In vivo distribution of ECM/Tel in mouse orthotopic 4T1 breast cancer model. Red circle: tumor area. (D) Fluorescence distribution of organs and tumors after dissection. (E) Semi-quantitative analysis of tumor fluorescence. ***P < 0.001.CC BY-NC · PubMed Central
Figure 3 Resting effect of ECM/Tel and permeability changes of MCSs. (A) α-SMA immunofluorescence staining of NIH/3T3 with different treatments (with or without 8 Gy irradiation) and A-NIH/3T3 with different treatments (Tel or ECM/Tel for 48 h, Tel = 2 μg/mL). Blue: DAPI, red: α-SMA. Scale bar: 20 μm. (B) Semi-quantitative analysis of α-SMA staining. (C) Western blot assay of α-SMA and related proteins in the TGF-β/Smads pathway in a. NIH/3T3, b. NIH/3T3+8 Gy, c. A-NIH/3T3, d. A-NIH/3T3+Tel, e. A-NIH/3T3+ECM/Tel groups. (D) Changes in the permeability of cell spheroids after treatment with Tel and ECM/Tel (Tel = 2 μg/mL, 48 h). Red: DiI, scale bar: 50 μm. *P < 0.05, **P < 0.01.
Figure 3 Resting effect of ECM/Tel and permeability changes of MCSs. (A) α-SMA immunofluorescence staining of NIH/3T3 with different treatments (with or without 8 Gy irradiation) and A-NIH/3T3 with different treatments (Tel or ECM/Tel for 48 h, Tel = 2 μg/mL). Blue: DAPI, red: α-SMA. Scale bar: 20 μm. (B) Semi-quantitative analysis of α-SMA staining. (C) Western blot assay of α-SMA and related proteins in the TGF-β/Smads pathway in a. NIH/3T3, b. NIH/3T3+8 Gy, c. A-NIH/3T3, d. A-NIH/3T3+Tel, e. A-NIH/3T3+ECM/Tel groups. (D) Changes in the permeability of cell spheroids after treatment with Tel and ECM/Tel (Tel = 2 μg/mL, 48 h). Red: DiI, scale bar: 50 μm. *P < 0.05, **P < 0.01.CC BY-NC · PubMed Central
Figure 4 Changes in the tumor microenvironment of mice treated with ECM/Tel. (A) Immunohistochemical staining for HIF-1α. (B) Masson staining. Scale bar: 100 μm. (C) Collagen I immunofluorescent staining. Scale bar: 50 μm. (D) Semi-quantitative analysis of HIF-1α. (E) Semi-quantitative determination of Masson’s staining. (F) Semi-quantitative assay of Collagen immunofluorescence staining. NS: no significant difference, *P < 0.05, **P < 0.01.
Figure 4 Changes in the tumor microenvironment of mice treated with ECM/Tel. (A) Immunohistochemical staining for HIF-1α. (B) Masson staining. Scale bar: 100 μm. (C) Collagen I immunofluorescent staining. Scale bar: 50 μm. (D) Semi-quantitative analysis of HIF-1α. (E) Semi-quantitative determination of Masson’s staining. (F) Semi-quantitative assay of Collagen immunofluorescence staining. NS: no significant difference, *P < 0.05, **P < 0.01.CC BY-NC · PubMed Central
Figure 5 Effect of ECM/Tel on 4T1 cell cycle. (A) The cell cycle of 4T1 treated with Tel or ECM/Tel was measured by flow cytometry. (B) Cell cycle quantification results of 4T1 after Tel or ECM/Tel treatment (C) Immunofluorescence staining of cyclin D1. (D) Immunofluorescence staining of cyclin A2. (E) Western blot determination of cyclinA2, cyclinB1 and cyclinD1. (F) Semi-quantitative analysis of immunofluorescence staining for cyclin D1. (G) Semi-quantitative analysis of immunofluorescence staining for cyclin A2. Scale bar: 50 μm. **P < 0.01, ***P < 0.001.
Figure 5 Effect of ECM/Tel on 4T1 cell cycle. (A) The cell cycle of 4T1 treated with Tel or ECM/Tel was measured by flow cytometry. (B) Cell cycle quantification results of 4T1 after Tel or ECM/Tel treatment (C) Immunofluorescence staining of cyclin D1. (D) Immunofluorescence staining of cyclin A2. (E) Western blot determination of cyclinA2, cyclinB1 and cyclinD1. (F) Semi-quantitative analysis of immunofluorescence staining for cyclin D1. (G) Semi-quantitative analysis of immunofluorescence staining for cyclin A2. Scale bar: 50 μm. **P < 0.01, ***P < 0.001.CC BY-NC · PubMed Central
Figure 6 Colony formation assay of 4T1 treated with ECM/Tel and radiation-sensitizing effect of ECM/Tel in MCSs. (A) Photographs of colony formation in each group. (B) Morphological changes of MCSs in 3 days. (C) Number of colonies in each group. (D) Diameters of MCSs over 3 days in each group. Scale bar: 0.1 mm. NS: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 6 Colony formation assay of 4T1 treated with ECM/Tel and radiation-sensitizing effect of ECM/Tel in MCSs. (A) Photographs of colony formation in each group. (B) Morphological changes of MCSs in 3 days. (C) Number of colonies in each group. (D) Diameters of MCSs over 3 days in each group. Scale bar: 0.1 mm. NS: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC · PubMed Central
Figure 7 Radiosensitizing efficacy of ECM/Tel in BALB/c mice. (A) Schematic of animal administration regimen. (B) Tumor morphology of mice in each group after dissection. (C) Tumor weights of mice in each group after dissection. (D) Tumor volume changes of mice in each group. (E) Bouin solution staining of lungs in each group. Red arrows indicate the location of the tumor metastasis in the lung. (F) Number of tumor nodules on the lungs in each group. (G) H&E staining of lungs in each group. Scale bar = 100 μm. NS: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 7 Radiosensitizing efficacy of ECM/Tel in BALB/c mice. (A) Schematic of animal administration regimen. (B) Tumor morphology of mice in each group after dissection. (C) Tumor weights of mice in each group after dissection. (D) Tumor volume changes of mice in each group. (E) Bouin solution staining of lungs in each group. Red arrows indicate the location of the tumor metastasis in the lung. (F) Number of tumor nodules on the lungs in each group. (G) H&E staining of lungs in each group. Scale bar = 100 μm. NS: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC · PubMed Central
Figure 8 Investigation of tumor properties in all groups. (A) α-SMA immunofluorescence staining. Blue: DAPI, red: α-SMA. (B) Masson staining of each group. (C) Ki67 staining of each group. (D) HIF-1α immunofluorescence staining of each group. (E) Semi-quantitative results of Masson staining. (F) Semi-quantitative results of Ki67 staining. (G) Semi-quantitative results of HIF-1α staining. n = 3. (H) Western blot assay of TGF-β/Smads pathway proteins. a: saline, b: Tel, c: ECM/Tel, d: saline+8 Gy, e: Tel+8 Gy, f: ECM/Tel+8 Gy. Scale bar: 100 μm. NS: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.
Figure 8 Investigation of tumor properties in all groups. (A) α-SMA immunofluorescence staining. Blue: DAPI, red: α-SMA. (B) Masson staining of each group. (C) Ki67 staining of each group. (D) HIF-1α immunofluorescence staining of each group. (E) Semi-quantitative results of Masson staining. (F) Semi-quantitative results of Ki67 staining. (G) Semi-quantitative results of HIF-1α staining. n = 3. (H) Western blot assay of TGF-β/Smads pathway proteins. a: saline, b: Tel, c: ECM/Tel, d: saline+8 Gy, e: Tel+8 Gy, f: ECM/Tel+8 Gy. Scale bar: 100 μm. NS: no significant difference, *P < 0.05, **P < 0.01, ***P < 0.001.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 4

  1. De Gasparo, 2000, Pharmacol Rev, 52, 415
  2. Amaya, 2004, Int J Oncol, 25, 849
  3. Song, 1998, J Environ Pathol Toxicol Oncol, 17, 141
  4. Parshad, 1984, Cancer Res, 44, 5577

Cited by

See all 7

Metadata

Authors
Chen, S., Wang, C., Meng, Y., Li, P., Pan, Y., He, M., & Ni, X.
Affiliations
  • Changzhou No.2 People's Hospital (CN)
  • Changzhou University (CN)
Corresponding author
Ni, Xinye
Venue
International Journal of Nanomedicine
Published
2024-02
Volume
Volume 19
Pages
1487-1508
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
OpenAlex
W4391849060
Cited by
7
References
67
Citations by year
2026: 2 · 2025: 4 · 2024: 1
FWCI
0.66
Type
journal article
Language
en
Open access
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • National Children's Research Centre
  • Jiangsu Commission of Health
  • National Natural Science Foundation of China (82303692, 81871756)
  • Nanjing Medical University
  • Jiangsu Provincial Key Research and Development Program (BE2022720)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords
telmisartan, nanoparticle drug delivery, radiosensitization, cancer-associated fibroblasts, tumor stroma, breast cancer, 4T1 cells, lung metastasis, tumor hypoxia, tumor microenvironment, G2/M cell cycle arrest, nanoparticle self-assembly
MeSH terms
Telmisartan, Animals, Hypoxia, Erythrocyte Membrane, Lung Neoplasms, Radiation Tolerance, Vascular Neoplasms, Cell Line, Tumor, Mice, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.